Amazon Web Services joins NIH’s STRIDES Initiative

Researchers associated with the National Institutes of Health (NIH) will have more resources to access and analyze data thanks to a new partnership with Amazon Web Services (AWS).

The newly-formed partnership with NIH’s Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability (STRIDES) Initiative will give NIH-associated biomedical researchers access to AWS technologies. AWS is Amazon's cloud-based computing platform subsidiary. 

“Teaming with Amazon Web Services will give NIH researchers powerful cloud-based resources to more efficiently collaborate and analyze data,” Andrea T. Norris, director of NIH’s Center for Information Technology and NIH CIO, said in a statement. “Expanding our cloud service provider network will allow us to provide the research community access to the tools they need to advance science.”

Launched earlier this year, the STRIDES Initiative seeks to utilize commercial cloud computing for biomedical researchers and make high-value data sets more accessible, interoperable and reusable in the cloud.

“We’re committed to providing those researchers participating in the STRIDES Initiative with access to high-value NIH datasets, enabling them to further their research to study, treat, and prevent the most devastating diseases,” Teresa Carlson, vice president of Worldwide Public Sector at AWS, said in a statement.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.